[1] |
中国医师协会急诊医师分会,中国研究型医院学会休克与脓毒症专业委员会. 中国脓毒症/脓毒性休克急诊治疗指南(2018)[J]. 感染、炎症、修复,2019, 20(1): 3-22.
|
[2] |
Xie J, Wang H, Kang Y, et al. The Epidemiology of Sepsis in Chinese ICUs: A National Cross-Sectional Survey[J]. Crit Care Med, 2020, 48(3): e209-e218.
|
[3] |
Paoli CJ, Reynolds MA, Sinha M, et al. Epidemiology and Costs of Sepsis in the United States-An Analysis Based on Timing of Diagnosis and Severity Level[J]. Crit Care Med, 2018, 46(12): 1889-1897.
|
[4] |
Gaieski DF, Edwards JM, Kallan MJ, et al. Benchmarking the incidence and mortality of severe sepsis in the United States[J]. Crit Care Med, 2013, 41(5): 1167-1174.
|
[5] |
中国医疗保健国际交流促进会急诊医学分会,中华医学会急诊医学分会,中国医师协会急诊医师分会,等. 中国脓毒症早期预防与阻断急诊专家共识[J]. 临床急诊杂志,2020, 21(7): 517-529.
|
[6] |
Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)[J]. JAMA, 2016, 315(8): 801-810.
|
[7] |
Freund Y, Lemachatti N, Krastinova E, et al. Prognostic Accuracy of Sepsis-3 Criteria for In-Hospital Mortality Among Patients With Suspected Infection Presenting to the Emergency Department[J]. JAMA, 2017, 317(3): 301-308.
|
[8] |
Mcgrath SP, Perreard I, Mackenzie T, et al. Improvement of sepsis identification through multi-year comparison of sepsis and early warning scores[J]. Am J Emerg Med, 2022, 51: 239-247.
|
[9] |
Usman OA, Usman AA, Ward MA. Comparison of SIRS, qSOFA, and NEWS for the early identification of sepsis in the Emergency Department[J]. Am J Emerg Med, 2019, 37(8): 1490-1497.
|
[10] |
陈师林,王兰,邓亚萍. 脓毒症早期识别及评估预后的生物标志物的研究进展[J]. 中国医药导报,2019, 16(10): 52-55.
|
[11] |
郭磊,沈华,张铮. 脓毒症的新型生物标志物研究进展[J]. 内科急危重症杂志,2020, 26(2): 155-158.
|
[12] |
刘昌,张靖垚. 腹腔感染诊治新理念:共识与争议[J]. 中国实用外科杂志,2019, 39(0): 538-541.
|
[13] |
Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock[J]. N Engl J Med, 2001, 345(19): 1368-1377.
|
[14] |
ProCESS Investigators, Yealy DM, Kellum JA, et al. A randomized trial of protocol-based care for early septic shock[J]. N Engl J Med, 2014, 370(18): 1683-1693.
|
[15] |
ARISE Investigators, ANZICS Clinical Trials Group, Peake SL, et al. Goal-directed resuscitation for patients with early septic shock[J]. N Engl J Med, 2014, 371(16): 1496-1506.
|
[16] |
Lilly CM. The ProCESS trial--a new era of sepsis management[J]. N Engl J Med, 2014, 370(18): 1750-1751.
|
[17] |
任建安. 脓毒症液体治疗争论与进展[J]. 中国实用外科杂志,2020, 40(1): 33-36.
|
[18] |
Levy MM, Evans LE, Rhodes A. The Surviving Sepsis Campaign Bundle: 2018 Update[J]. Crit Care Med, 2018, 46(6): 997-1000.
|
[19] |
Brown RM, Wang L, Coston TD, et al. Balanced Crystalloids versus Saline in Sepsis. A Secondary Analysis of the SMART Clinical Trial[J]. Am J Respir Crit Care Med, 2019, 200(12): 1487-1495.
|
[20] |
毛小强,楼炳恒,吴德军. 乳酸林格氏液与生理盐水对脓毒性休克患者临床疗效的比较[J]. 中国医学科学院学报,2018, 40(3): 349-355.
|
[21] |
Casey JD, Brown RM, Semler MW. Resuscitation fluids[J]. Curr Opin Crit Care, 2018, 24(6): 512-518.
|
[22] |
Orbegozo Cortés D, Gamarano Barros T, Njimi H, et al. Crystalloids versus colloids: exploring differences in fluid requirements by systematic review and meta-regression[J]. Anesth Analg, 2015, 120(2): 389-402.
|
[23] |
Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016[J]. Intensive Care Med, 2017, 43(3): 304-377.
|
[24] |
Antal O, Ştefãnescu E, Mleşnie M, et al. Initial Fluid Resuscitation Following Adjusted Body Weight Dosing in Sepsis and Septic Shock[J]. J Crit Care Med (Targu Mures), 2019, 5(4): 130-135.
|
[25] |
Butz J, Shan Y, Samayoa A, et al. The utility of impedance cardiography in hemodynamic monitoring of patients with sepsis[J]. Trauma Surg Acute Care Open, 2019, 4(1): e000349.
|
[26] |
Liu VX, Fielding-Singh V, Greene JD, et al. The Timing of Early Antibiotics and Hospital Mortality in Sepsis[J]. Am J Respir Crit Care Med, 2017, 196(7): 856-863.
|
[27] |
Klompas M, Calandra T, Singer M. Antibiotics for Sepsis-Finding the Equilibrium[J]. JAMA, 2018, 320(14): 1433-1434.
|
[28] |
Minderhoud TC, Spruyt C, Huisman S, et al. Microbiological outcomes and antibiotic overuse in Emergency Department patients with suspected sepsis[J]. Neth J Med, 2017, 75(5): 196-203.
|
[29] |
Schinkel M, Nannan Panday RS, Wiersinga WJ, et al. Timeliness of antibiotics for patients with sepsis and septic shock[J]. J Thorac Dis, 2020, 12(Suppl 1): S66-S71.
|
[30] |
Nannan Panday RS, Wang S, van de Ven PM, et al. Evaluation of blood culture epidemiology and efficiency in a large European teaching hospital[J]. PLoS One, 2019, 14(3): e0214052.
|
[31] |
Campion M, Scully G. Antibiotic Use in the Intensive Care Unit: Optimization and De-Escalation[J]. J Intensive Care Med, 2018, 33(12): 647-655.
|
[32] |
Opal SM, Garber GE, Larosa SP, et al. Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated)[J]. Clin Infect Dis, 2003, 37(1): 50-58.
|
[33] |
Prout AJ, Talisa VB, Carcillo JA, et al. Bacterial and Fungal Etiology of Sepsis in Children in the United States: Reconsidering Empiric Therapy[J]. Crit Care Med, 2020, 48(3): e192-e199.
|
[34] |
Rhee C, Kadri SS, Dekker JP, et al. Prevalence of Antibiotic-Resistant Pathogens in Culture-Proven Sepsis and Outcomes Associated With Inadequate and Broad-Spectrum Empiric Antibiotic Use[J]. JAMA Netw Open, 2020, 3(4): e202899.
|
[35] |
Noll I, Schweickert B, Abu Sin M, et al. [Antimicrobial resistance in Germany. Four years of antimicrobial resistance surveillance (ARS)][J]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, 2012, 55(11/12): 1370-1376.
|
[36] |
吴健锋,裴飞. 脓毒症免疫治疗的研究现状[J]. 医学研究生学报,2019, 32(1): 37-42.
|
[37] |
张文杰,何英丽,常雪妮,等. 脓毒症治疗新视野:免疫治疗研究进展[J]. 中国实用内科杂志,2019, 39(8): 735-739.
|
[38] |
Fallon EA, Chung CS, Heffernan DS, et al. Survival and Pulmonary Injury After Neonatal Sepsis: PD1/PDL1′s Contributions to Mouse and Human Immunopathology[J]. Front Immunol, 2021, 12: 634529.
|
[39] |
Wilson JK, Zhao Y, Singer M, et al. Lymphocyte subset expression and serum concentrations of PD-1/PD-L1 in sepsis - pilot study[J]. Crit Care, 2018, 22(1): 95.
|
[40] |
Watanabe E, Thampy LK, Hotchkiss RS. Immunoadjuvant therapy in sepsis: novel strategies for immunosuppressive sepsis coming down the pike[J]. Acute Med Surg, 2018, 5(4): 309-315.
|
[41] |
Kim EY, Ner-Gaon H, Varon J, et al. Post-sepsis immunosuppression depends on NKT cell regulation of mTOR/IFN-γ in NK cells[J]. J Clin Invest, 2020, 130(6): 3238-3252.
|
[42] |
Schütze S, Kaufmann A, Bunkowski S, et al. Interferon-gamma impairs phagocytosis of by primary murine peritoneal macrophages stimulated with LPS and differentially modulates proinflammatory cytokine release[J]. Cytokine X, 2021, 3(3): 100057.
|
[43] |
Kox WJ, Bone RC, Krausch D, et al. Interferon gamma-1b in the treatment of compensatory anti-inflammatory response syndrome. A new approach: proof of principle[J]. Arch Intern Med, 1997, 157(4): 389-393.
|
[44] |
Fu J, Yi Z, Cui H, et al. Intein-mediated expression and purification of common carp IFN-γ and its protective effect against spring viremia of carp virus[J]. Fish Shellfish Immunol, 2019, 88: 403-406.
|
[45] |
Monneret G, Venet F. Sepsis-induced immune alterations monitoring by flow cytometry as a promising tool for individualized therapy[J]. Cytometry B Clin Cytom, 2016, 90(4): 376-386.
|
[46] |
Kashiouris MG, L′heureux M, Cable CA, et al. The Emerging Role of Vitamin C as a Treatment for Sepsis[J]. Nutrients, 2020, 12(2): 292.
|
[47] |
吕清泉,顾小花,吕应鸣,等. 维生素C在脓毒症中的应用进展[J/CD]. 中华重症医学电子杂志(网络版), 2020, 6(1): 104-108.
|
[48] |
牛京京,秦秉玉,杨凯丽,等. 早期补充维生素C对脓毒症患者预后的影响[J]. 中国现代医学杂志,2019, 29(23): 65-69.
|
[49] |
Menich BE, Miano TA, Patel GP, et al. Norepinephrine and Vasopressin Compared With Norepinephrine and Epinephrine in Adults With Septic Shock[J]. Ann Pharmacother, 2019, 53(9): 877-885.
|
[50] |
Xing X, Zhi Y, Lu J, et al. Traditional Chinese medicine bundle therapy for septic acute gastrointestinal injury: A multicenter randomized controlled trial[J]. Complement Ther Med, 2019, 47: 102194.
|
[51] |
孙荣青,梁明,杨宏富,等. 血必净对脓毒性休克患者炎症反应及预后的影响[J]. 中华危重病急救医学,2020, 32(4): 458-462.
|